Perlove

Perlove Medical is a major Chinese medical X-ray imaging system supplier — the company describes itself as the second-largest in this segment domestically — and became the first Chinese manufacturer to receive NMPA approval for an integrated orthopedic surgical robot and 3D C-arm solution. With over two decades of experience in medical imaging technology, the company has expanded from a single product line to more than 100 equipment models serving hospitals across China and in over 200 countries worldwide.

Company Overview

Established in Nanjing in 2003, Perlove Medical built its foundation on X-ray imaging technology, developing proprietary capabilities in X-ray tube assemblies, high-voltage generators, and three-dimensional imaging systems. The company achieved a significant milestone in 2012 when its independently developed 3D C-arm received China’s first Class III medical device registration certificate for flat-panel 3D C-arm systems. That same year, Perlove initiated its orthopedic surgical robot development project.

After a decade of research and development, Perlove launched its full-process solution combining orthopedic surgical robots with 3D C-arm imaging in 2022. The company operates two manufacturing facilities: the Nanjing base produces digital radiography (DR) systems, mobile C-arm X-ray machines, and the orthopedic surgical robot solution, while the Zhuhai facility manufactures DR and DRF (digital radiography and fluoroscopy) systems.

Perlove has been recognized as a National Specialized and Sophisticated SME (“Little Giant” enterprise) by China’s Ministry of Industry and Information Technology. The company filed for a Hong Kong Stock Exchange IPO in April 2025 following an earlier terminated ChiNext listing attempt in 2021.

Core Products

Megrez PL300B Orthopedic Surgical Robot

The Megrez PL300B represents Perlove’s flagship surgical robot product, receiving NMPA Class III registration in June 2022. Named after the fourth star in the Big Dipper constellation (known as “Tān Quán” or the star of wisdom in Chinese astrology), the system combines optical tracking with robotic arm positioning to assist orthopedic surgeons in minimally invasive procedures.

The robot integrates with Perlove’s proprietary 3D C-arm to provide intraoperative three-dimensional imaging with real-time navigation. This integration establishes automatic coordinate registration between the optical position finder, patient anatomy, and imaging data through adaptive registration technology. Clinical applications include spine surgery, orthopedic trauma procedures, and sacral nerve stimulator implantation.

Technology & Innovation

Perlove has developed ten core technology platforms: high-frequency inverter technology, system integration, dynamic imaging systems, 3D imaging, orthopedic intraoperative navigation, robotic arm navigation, DSA (digital subtraction angiography), roadmap imaging, computer oral panoramic simulation, intelligent control, and networked imaging.

The company’s integrated approach distinguishes it from competitors who typically source imaging equipment separately from surgical robots. By developing both the 3D C-arm and surgical robot in-house, Perlove achieves tighter coordination between imaging and navigation systems, enabling faster calibration and improved accuracy during procedures.

Market Presence

Perlove serves more than 1,200 hospitals and medical institutions in China, with its sales network covering all provinces. The company’s mobile C-arm X-ray machines represent approximately 50% of revenue, with the domestic market accounting for over 70% of total sales. Internationally, Perlove works with more than 200 distributors across five continents.

The company has participated in major industry events including Arab Health, RSNA (Radiological Society of North America), Medica, and CAOS (Chinese Association of Orthopaedic Surgeons) conferences, demonstrating its orthopedic surgical robot and imaging solutions to healthcare professionals globally.

Key Milestones

• 2003: Company founded in Nanjing
• 2012: Launched China’s first flat-panel 3D C-arm; initiated orthopedic surgical robot development
• 2017: Entered pre-IPO counseling with Jiangsu Securities Regulatory Bureau
• 2019: Conducted 5G-enabled remote surgical robot demonstration with China Telecom
• 2021: Filed ChiNext IPO application (later terminated)
• 2022: Megrez PL300B orthopedic surgical robot received NMPA approval (June)
• 2023: Held new product launch conference for orthopedic surgical robot
• 2025: Filed Hong Kong Stock Exchange IPO application (April)

Frequently Asked Questions

What makes Perlove’s surgical robot different from competitors?

Perlove is the first Chinese company to offer both the 3D C-arm imaging system and orthopedic surgical robot as an integrated solution from a single manufacturer. This integration provides better system compatibility, faster calibration, and more accurate coordination compared to systems assembled from different vendors.

What procedures can the Megrez PL300B perform?

The Megrez PL300B assists in spine surgery, orthopedic trauma procedures, and has been used for sacral nerve stimulator implantation. The robot enables surgeons to plan multiple pedicle screw paths in a single operation, reducing surgical time and improving placement accuracy to sub-millimeter precision.

Is Perlove Medical publicly traded?

Perlove is not currently publicly traded. The company filed for a Hong Kong Stock Exchange IPO in April 2025. A previous ChiNext listing attempt in 2021 was terminated. The company has completed multiple funding rounds through Series F, with the F-round valuation reaching approximately CNY 2 billion.